TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19294551

Group type: EXPERIMENTAL
Intervention: Acceptance of stuttering
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Work-related speaking situations
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Retirement
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Learned and self-devised techniques
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Desire for effective treatment
Number of subjects: 11
Study: 16546854

Group type: EXPERIMENTAL
Intervention: Toothpaste containing sodium fluoride (1500 ppm)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Toothpaste containing amine fluoride (1250 ppm)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 39
Study: 12662366

Group type: EXPERIMENTAL
Intervention: Energy prescription diet (n=16)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Healthy eating diet (n=11)
Number of subjects: 53
Study: 11138765

Group type: EXPERIMENTAL
Intervention: Stereotypic information about teammates (gender stereotypes in Experiment 1, occupational stereotypes in Experiments 2 to 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collective condition (Experiment 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipation of working on a collective task (Experiment 4)
Number of subjects: 0
Study: 9103704

Group type: EXPERIMENTAL
Intervention: Cholecystectomy without peritoneal closure (n = 63)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Cholecystectomy with peritoneal closure (n = 66)
Number of subjects: 129
Study: 1397878

Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg.kg‐1.h‐1)
Number of subjects: 12
Study: 4028627

Group type: EXPERIMENTAL
Intervention: Acifran 100 mg t.i.d.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acifran 300 mg t.i.d.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31601603

Group type: EXPERIMENTAL
Intervention: Antibiotic dispensing from private pharmacies
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Cefixime and third-generation cephalosporins
Number of subjects: 1537

Group type: COMPARATOR
Intervention: Unlicensed pharmacies
Number of subjects: 1537

Group type: COMPARATOR
Intervention: Young patients
Number of subjects: 1537
Study: 29340623

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) - four weekly infusions of 375 mg/m2
Number of subjects: 89
Study: 26829923

Group type: EXPERIMENTAL
Intervention: Maekmoondong-tang
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25537538

Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM) with positive end-expiratory pressure (PEEP)
Number of subjects: 30
Study: 22342390

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 150 mg/d
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 60 mg/d
Number of subjects: 51
Study: 20145599

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal renal artery stent placement (PTRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Embolic protection devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contrast induced nephropathy prevention practices
Number of subjects: 0
Study: 16705003

Group type: EXPERIMENTAL
Intervention: Systemic steroids (Methyl prednisolone 0.5 mg/kg/day i.v. in two divided doses)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nebulized steroids (Budecort 50 micrograms nebulized every 12 hours)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 51
Study: 16503676

Group type: EXPERIMENTAL
Intervention: Jump Squat (JS) group performed 1 set of 40‐kg LCMJs
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON) group performed 1 set of 20‐kg LCMJs
Number of subjects: 9
Study: 12900237

Group type: EXPERIMENTAL
Intervention: HumanOptics accommodating 1CU(R) IOL
Number of subjects: 42

Group type: COMPARATOR
Intervention: Eurocrystal IFP 3G 6.00 (control group)
Number of subjects: 42
Study: 10882616

Group type: EXPERIMENTAL
Intervention: zidovudine plus stavudine (d4T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: didanosine (ddI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: didanosine (ddI) plus zidovudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: zidovudine plus d4T
Number of subjects: 0
Study: 8761371

Group type: EXPERIMENTAL
Intervention: Serum prostate-specific antigen (PSA) screening
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Use of free to total PSA ratio with a cut-off level of 0.20
Number of subjects: 600
Study: 1555499

Group type: EXPERIMENTAL
Intervention: Hemodilution (group I): six venesections of 400 ml each followed by the injection of 500 ml low-molecular dextran (10%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pentoxifylline (group II): 400 mg four times daily by mouth after initial intravenous loading
Number of subjects: 20
Study: 3924216

Group type: EXPERIMENTAL
Intervention: Biosynthetic human insulin (1 mU/kg/min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin antibodies presence
Number of subjects: 24

Group type: COMPARATOR
Intervention: Insulin action loss rate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moderate concentrations of insulin antibodies
Number of subjects: 24
Study: 30134866

Group type: EXPERIMENTAL
Intervention: ASET
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: EW
Number of subjects: 144

Group type: COMPARATOR
Intervention: JNL
Number of subjects: 144
Study: 26526713

Group type: EXPERIMENTAL
Intervention: Etrolizumab (exact dosage and duration not specified)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Rectosigmoidoscopy
Number of subjects: 331

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 331

Group type: COMPARATOR
Intervention: Endoscopic healing defined as MCSe of 0
Number of subjects: 331
Study: 25051000

Group type: EXPERIMENTAL
Intervention: Vibration-enhanced static stretching
Number of subjects: 21

Group type: COMPARATOR
Intervention: Static stretching without vibration
Number of subjects: 21
Study: 22879417

Group type: EXPERIMENTAL
Intervention: PRK (n = 20)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LASIK (n = 25)
Number of subjects: 45
Study: 20730362

Group type: EXPERIMENTAL
Intervention: HVPC(-) group (conventional treatment plus negative polarity HVPC)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HVPC+ group (conventional treatment plus positive polarity HVPC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: CG (control group with conventional treatment)
Number of subjects: 28
Study: 18664156

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 32
Study: 15976242

Group type: COMPARATOR
Intervention: Capdevila approach (group C; n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified Winnie approach (group W; n = 30)
Number of subjects: 60
Study: 12721399

Group type: EXPERIMENTAL
Intervention: Selenium (Se)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Zinc (Zn)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Copper (Cu)
Number of subjects: 109
Study: 10469709

Group type: EXPERIMENTAL
Intervention: 5 mmol/l taurine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mmol/l glutamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mmol/l glutamine and 5 mmol/l taurine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention specified)
Number of subjects: 0
Study: 8694034

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 1913008

Group type: EXPERIMENTAL
Intervention: Evening primrose oil 6 g/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Olive oil 6 g/day (placebo)
Number of subjects: 40
Study: 7038918

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31904304

Group type: EXPERIMENTAL
Intervention: Serious Illness Care Program (SICG)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 159
Study: 30778558

Group type: EXPERIMENTAL
Intervention: Very low SQB (n = 213)
Number of subjects: 2309

Group type: EXPERIMENTAL
Intervention: Low SQB (n = 1035)
Number of subjects: 2309

Group type: EXPERIMENTAL
Intervention: High SQB (n = 588)
Number of subjects: 2309

Group type: EXPERIMENTAL
Intervention: Very high SQB (n = 473)
Number of subjects: 2309

Group type: EXPERIMENTAL
Intervention: Overall SQB levels
Number of subjects: 2309
Study: 29066597

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study: 26234526

Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23618891

Group type: EXPERIMENTAL
Intervention: Preventive consultation with occupational physician (41% of group 1)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: E-mental health intervention (16% of group 2)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: WHS mental module
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Overall WHS process
Number of subjects: 369
Study: 21212381

Group type: EXPERIMENTAL
Intervention: Story-focused brief with state-level data
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Data-focused brief with state-level data
Number of subjects: 291

Group type: COMPARATOR
Intervention: Data-focused brief with local-level data
Number of subjects: 291

Group type: COMPARATOR
Intervention: Story-focused brief with local-level data
Number of subjects: 291
Study: 18661066

Group type: EXPERIMENTAL
Intervention: Circumferential supracrestal fibrotomy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-surgery
Number of subjects: 21
Study: 16528713

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 90
Study: 12783053

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV, N = 18)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Resistance training (RES, N = 18)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo group (PL, N = 19)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (CO, N = 12)
Number of subjects: 67
Study: 10711541

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 41

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 41
Study: 9109102

Group type: EXPERIMENTAL
Intervention: D-cycloserine (15, 50, and 150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1591163

Group type: EXPERIMENTAL
Intervention: NHS nursing homes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional long stay hospital wards
Number of subjects: 0
Study: 3978996

Group type: EXPERIMENTAL
Intervention: Activated charcoal (225 gm)
Number of subjects: 10
Study: 30947915

Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RSD)
Number of subjects: 977
Study: 30622617

Group type: EXPERIMENTAL
Intervention: Superficial acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional acupuncture
Number of subjects: 40
Study: 28025355

Group type: EXPERIMENTAL
Intervention: 3-hour chronic pain educational session
Number of subjects: 346

Group type: COMPARATOR
Intervention: treatment as usual (normal wait-list)
Number of subjects: 346
Study: 26148947

Group type: EXPERIMENTAL
Intervention: Parent training program integrated into primary health center visits, delivered in group format at 5 routine visits from age 3 to 18 months, including short films, discussions, demonstrations, and distribution of message cards and play materials.
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Parent training program.
Number of subjects: 501
Study: 24220547

Group type: EXPERIMENTAL
Intervention: BEST MOOD (family based intervention)
Number of subjects: 160

Group type: COMPARATOR
Intervention: PAST (active control condition)
Number of subjects: 160
Study: 21348810

Group type: EXPERIMENTAL
Intervention: Oral levosimendan
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 18316716

Group type: EXPERIMENTAL
Intervention: Training with a single spatial frequency stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal observers
Number of subjects: 0
Study: 16536958

Group type: EXPERIMENTAL
Intervention: Perceived patient demand for antibiotics
Number of subjects: 1448

Group type: EXPERIMENTAL
Intervention: Normal lung auscultation with perceived patient demand
Number of subjects: 1448

Group type: EXPERIMENTAL
Intervention: One abnormal auscultatory finding with perceived patient demand
Number of subjects: 1448
Study: 14617264

Group type: EXPERIMENTAL
Intervention: VO2max in CHF patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: VO2max in control subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of VO2max with mean SDH activity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximum oxygen uptake rate per unit muscle fibre length
Number of subjects: 20
Study: 11712030

Group type: EXPERIMENTAL
Intervention: PDGF gel
Number of subjects: 7

Group type: COMPARATOR
Intervention: Antibiotic ointment
Number of subjects: 7
Study: 9696196

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis for cervicitis
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis for trichomoniasis
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Laboratory tests for gonorrhoea, chlamydia infection, and trichomoniasis
Number of subjects: 1233
Study: 8063984

Group type: EXPERIMENTAL
Intervention: Intensive, individualized cognitive therapy (10 sessions over 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Daily gastrointestinal (GI) symptom monitoring (8 weeks)
Number of subjects: 20
Study: 3194864

Group type: EXPERIMENTAL
Intervention: 1.25 mg terbutaline (five puffs)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31049671

Group type: EXPERIMENTAL
Intervention: Single-session music intervention (SMI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 27940291

Group type: EXPERIMENTAL
Intervention: Retromuscular mesh repair
Number of subjects: 180

Group type: COMPARATOR
Intervention: Onlay technique
Number of subjects: 180
Study: 25323734

Group type: EXPERIMENTAL
Intervention: Taurine (2 g per day orally, divided into two doses, taken 6 h after chemotherapeutic agents)
Number of subjects: 40
Study: 23297332

Group type: EXPERIMENTAL
Intervention: Digital mammography plus tomosynthesis
Number of subjects: 12631

Group type: COMPARATOR
Intervention: Digital mammography alone
Number of subjects: 12631
Study: 21330902

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Neurotoxic ART (nART)
Number of subjects: 2141
Study: 19815817

Group type: EXPERIMENTAL
Intervention: ITX5061
Number of subjects: 0
Study: 16452592

Group type: EXPERIMENTAL
Intervention: Inhaled heparin (50,000 IU, twice daily for 2 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14977665

Group type: EXPERIMENTAL
Intervention: Suture anchor fixation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Bone tunnel fixation
Number of subjects: 9
Study: 11977347

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy using abdominal wall lift
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy using pneumoperitoneum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 0
Study: 9447290

Group type: EXPERIMENTAL
Intervention: Mutation at codon 918 (ATG to ACG) found in peripheral blood and MTC tissue from the MEN 2B patient.
Number of subjects: 7

Group type: COMPARATOR
Intervention: PCR-SSCP analysis of exons 10 and 11, and restriction enzyme digestion methods for exons 13 and 16.
Number of subjects: 7
Study: 7523548

Group type: EXPERIMENTAL
Intervention: CYFRA 21-1 serum levels
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: CEA serum levels
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: CA 125 serum levels
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: SCC serum levels
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: NSE serum levels
Number of subjects: 239
Study: 31327563

Group type: EXPERIMENTAL
Intervention: 7 days of supervised primaquine (1·0 mg/kg per day)
Number of subjects: 2336

Group type: EXPERIMENTAL
Intervention: 14 days of supervised primaquine (0·5 mg/kg per day)
Number of subjects: 2336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2336

Group type: EXPERIMENTAL
Intervention: 7 days of primaquine
Number of subjects: 2336

Group type: EXPERIMENTAL
Intervention: 14 days of primaquine
Number of subjects: 2336
Study: 29216446

Group type: EXPERIMENTAL
Intervention: Low volume per session with high frequency (LV-HF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High volume per session with low frequency (HV-LF)
Number of subjects: 18
Study: 27002161

Group type: EXPERIMENTAL
Intervention: Empathy group (brief empathetic statements included)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Non-empathy group (no empathetic statements)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Empathy group
Number of subjects: 437
Study: 24821096

Group type: EXPERIMENTAL
Intervention: 1-session intervention utilizing psychoeducation and interoceptive exposure techniques to target anxiety sensitivity (AS)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Health information control intervention
Number of subjects: 108
Study: 22924607

Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (4000-100,000 IU per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20453562

Group type: EXPERIMENTAL
Intervention: Teaching method using Standardized Patients (SPs)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional practice education (Control)
Number of subjects: 62
Study: 18716497

Group type: EXPERIMENTAL
Intervention: Microneedles (various designs)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Microneedle length
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Number of microneedles
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Microneedle tip angle, thickness, and width
Number of subjects: 10

Group type: COMPARATOR
Intervention: 26-gauge hypodermic needle
Number of subjects: 10
Study: 16042223

Group type: EXPERIMENTAL
Intervention: IFNβ‐1a‐Avonex 30 μg intramuscularly once weekly for six years
Number of subjects: 382
Study: 12629096

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10337083

Group type: EXPERIMENTAL
Intervention: Postal Group
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Telephone Group
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Face-to-face Group
Number of subjects: 360
Study: 9112170

Group type: EXPERIMENTAL
Intervention: Trephination with scleral auto-implant plug soaked with Mitomycin-C (0.2 mg/ml for 5 minutes)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Trabeculectomy with Mitomycin-C
Number of subjects: 67
Study: 1748532

Group type: EXPERIMENTAL
Intervention: Plasmapheresis and subsequent pulse cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pulse cyclophosphamide alone
Number of subjects: 0
Study: 7095718

Group type: EXPERIMENTAL
Intervention: High protein isocaloric diet for seven days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low protein isocaloric diet for seven days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low protein diet
Number of subjects: 24
Study: 28838290

Group type: EXPERIMENTAL
Intervention: Modified Behavioral Activation Treatment (MBAT) for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Regular treatment (Control)
Number of subjects: 80
Study: 29986673

Group type: EXPERIMENTAL
Intervention: Genomic sequencing and report including monogenic disease variants, recessive carrier variants, and pharmacogenomic variants.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving genomic sequencing).
Number of subjects: 0
Study: 26711160

Group type: EXPERIMENTAL
Intervention: Dronabinol 20 mg three times a day and lofexidine 0.6 mg three times a day
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 24853059

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment protocol (CBSPp) with treatment as usual (TAU), 24 sessions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment protocol (CBSPp)
Number of subjects: 49
Study: 23042121

Group type: EXPERIMENTAL
Intervention: Hypothetical leadership position with both social and financial resources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypothetical leadership position with financial resources but no social resources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypothetical leadership position with social resources but no financial resources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women's evaluations of leadership positions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Men's evaluations of leadership positions
Number of subjects: 0
Study: 20931422

Group type: EXPERIMENTAL
Intervention: Probiotic-containing yogurt (Bifidobacterium DN-173 010-1010 cfu/g) 125 ml before breakfast for 14 days
Number of subjects: 76

Group type: COMPARATOR
Intervention: Triple therapy (pantoprazole 40 mg b.i.d., amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d. for 14 days)
Number of subjects: 76
Study: 18809049

Group type: EXPERIMENTAL
Intervention: MarginProbe device
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 300
Study: 16190915

Group type: EXPERIMENTAL
Intervention: 2.5 mg naratriptan
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 12352805

Group type: EXPERIMENTAL
Intervention: Protease inhibitors (indinavir, saquinavir, ritonavir, nelfinavir)
Number of subjects: 68
Study: 9935109

Group type: EXPERIMENTAL
Intervention: 12.5 mg of IM progesterone given 12 hours before oocyte retrieval
Number of subjects: 314

Group type: COMPARATOR
Intervention: 25 mg of IM progesterone given on the day of oocyte retrieval
Number of subjects: 314